Table 2.
Laboratory markers in groups of CAD.
|
All patients (N = 120) |
CAD pos. | CAD neg. | |||
|---|---|---|---|---|---|
| MVD (N = 36) |
SVD (N = 26) |
Insignificant atherosclerosis (N = 38) |
Control group (N = 20) |
||
| Laboratory markers | |||||
| HP Seropositive (%)†§ | 62.5 | 76.3#¥ | 70# | 52.8 | 50 |
| CRP† | 6.25 (4.55–7.95) | 6.2 (2–10.2) | 8.4* (3.8–13.1) | 5.2 (3.7–6.7) | 5.5 (2.4–8.6) |
| ESR†§ | 13.7 (11.1–16.3) | 17.2* (10.8–23.5) | 17* (10.7–23.3) | 10.3 (7.1–13.5) | 9.5 (5.2–13.8) |
| Total Chol | 145 (138–152) | 155.5 (142.5–168.5) | 136.5 (122.3–150.7) | 144.2 (132.6–155.8) | 138.8 (120–157.8) |
| HDL†† | 48.5 (46.6–50.4) | 49.5 (45.9–52.9) | 43.8 (39.1–48.5)## | 53.6 (50.5–56.7)** | 43.2 (39.9–46.5) |
| TG | 149.7 (133.3–166.1) | 154.6 (123–186.2) | 150.7 (120.9–180.3) | 140.9 (111.3–170.5) | 156 (104.5–208.1) |
| LDL | 69.6 (63.1–76.1) | 79.3 (66.1–92.5) | 61.8 (49.7–73.9) | 68.6 (55.2–82) | 64 (52–76) |
| Creatinine† | 1.08 (0.95–1.2) | 1.06 (0.99–1.2) | 0.94 (0.89–1)* | 0.95 (0.9–1)* | 1.5 (0.76–2.2) |
Categorical variables are presented in %, continuous variables as mean (95% confidence interval), and due to not normal distribution logarithmic transformation of the data was needed.†significant difference among groups: ANOVA/Chi-square test (P < 0.050), ††significant difference among groups: ANOVA/Chi-square test (P < 0.001), §significant difference between CAD pos. and CAD neg.: Chi-square test (P < 0.050), #significant difference versus insignificant atherosclerosis: Chi-square test (P < 0.050), ##significant difference versus insignificant atherosclerosis: Bonferroni test (P < 0.001), *significant difference versus control group: Bonferroni test (P < 0.05), **significant difference versus control group: Bonferroni test (P < 0.001), and ¥significant difference versus control group: Chi-square test (P < 0.050).